

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT application of)	
Tohru NATSUME et al.)	
Application No. 10/581,969)	Confirmation No. 8384
Filed: June 7, 2006)	Group Art Unit: 1656
For: NOVEL INTERACTION BETWEEN PROTEINS, AND THERAPEUTIC AGENT FOR DISUSE MUSCULAR ATROPHY OR METHOD ASSOCIATED WITH DISUSE MUSCULAR ATROPHY TAKING ADVANTAGE OF NOVEL INTERACTION)	Examiner: Maryam Monshipouri

SECOND RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Sir:

In response to the second Restriction Requirement mailed May 8, 2009, Applicant elects the claims of Group 2 and Group I(F) without traverse, i.e. claim 19, drawn to a method for screening therapeutic agents for disuse muscular atrophy comprising the step of interacting the protein defined in claim 14 with a polyubiquitin chain.

This response is accompanied by a Second Preliminary Amendment which appropriately amends the claims of Group 1(F), withdraws the unelected claims, and adds new claims dependent upon elected claim 19.

Respectfully submitted,

Dated: May 28, 2009



Thomas W. Cole
Registration No. 28,290

Customer No. 25570

Roberts Mlotkowski Safran & Cole, P.C.
P.O. Box 10064
McLean, VA 22102
Telephone: (703) 677-3001